The Structure, Function and Evolution of Biological Networks
1: Gene Regulatory Networks
2: Regulation of Metabolic Networks
1: Gene Regulatory Networks
2: Regulation of Metabolic Networks
Dr. Walhout provides perspective in the April 20 issue of Science on the latest Research Article from a longstanding collaboration between Brenda Andrews and Charles Boone at the University of Toronto, and Chad Myers from the University of Minnesota. These groups constructed the first large scale trigenic interaction map of genes that affect colony growth in the yeast S. cerevisiae. The growth of these triple-deletion strains was compared with the growth of the strains harboring single or double deletions in the relevant genes. Given that a total of 36 billion potential trigenic interactions can occur in yeast, this study starts with a set of query strains carrying 302 single gene mutations and 151 double gene mutations. These query strains were tested for genetic interactions versus an array of 1182 strains, each carrying a mutation in an informative gene, so that most general biological processes were included. Thus, in total close to 200,000 trigenic interactions (∼0.0006% of all possible combinations) were tested. Dr. Walhout discusses the implications and future directions from the results of this study.
Walhout AJM (2018). If two deletions don’t stop growth, try three. Science, 360(6386), 269–270.
Kuzmin E, VanderSluis B, Wang W, Tan G, Deshpande R, Chen Y, Usaj M, Balint A, Mattiazzi Usaj M, van Leeuwen J, Koch EN, Pons C, Dagilis AJ, Pryszlak M, Wang JZY, Hanchard J, Riggi M, Xu K, Heydari H, San Luis BJ, Shuteriqi E, Zhu H, Van Dyk N, Sharifpoor S, Costanzo M, Loewith R, Caudy A, Bolnick D, Brown GW, Andrews BJ, Boone C, Myers CL. (2018). Systematic analysis of complex genetic interactions. Science, 360(6386).
Vitamin B12 functions as a cofactor for methionine synthase to produce the anabolic methyl donor S-adenosylmethionine (SAM) and for methylmalonyl-CoA mutase to catabolize the short-chain fatty acid propionate. In the nematode Caenorhabditis elegans, maternally supplied vitamin B12 is required for the development of offspring. However, the mechanism for exporting vitamin B12 from the mother to the offspring is not yet known. Here, we use RNAi of more than 200 transporters with a vitamin B12-sensor transgene to identify the ABC transporter MRP-5 as a candidate vitamin B12 exporter. We show that the injection of vitamin B12 into the gonad of mrp-5 deficient mothers rescues embryonic lethality in the offspring. Altogether, our findings identify a maternal mechanism for the transit of an essential vitamin to support the development of the next generation.
Huimin N, Ponomarova O, Giese GE, Walhout AJM. (2018). C. elegans MRP-5 Exports Vitamin B12 from Mother to Offspring to Support Embryonic Development. Cell Reports 22, 3126-3133.
The January, 2018, issue of Cold Spring Harbor Protocols features three protocols on Gateway recombinatorial cloning for use in high-throughput studies.
The Gateway recombinatorial cloning system was developed for cloning multiple DNA fragments in parallel (e.g., in 96-well formats) in a standardized manner using the same enzymes. Gateway cloning is based on the highly specific integration and excision reactions of bacteriophage λ into and out of the Escherichia coli genome. Because the sites of recombination (“att” sites) are much longer (25–242 bp) than restriction sites, they are extremely unlikely to occur by chance in DNA fragments. Therefore, the same recombination enzyme can be used to robustly clone many different fragments of variable size in parallel reactions.
Reece-Hoyes JS, Walhout AJM. (2018) Gateway Recombinational Cloning. Cold Spring Harb. Protoc. 2018(1).
The microbiota plays a critical role in human health and disease. For instance, the gut microbiota aides in the digestion of foods, thereby contributing to our ability to metabolize compounds from our diet. Recently, it has become clear that the microbiota can also play an important role in the response to medications. However, several limitations in utilizing mammalian model systems, such as complex microbiota, high cost, and limited scalability, have constrained our ability to systematically test which bacteria affect the drug response and the mechanisms involved. The nematode Caenorhabditis elegans and its bacterial diet provide a facile interspecies model system to identify and characterize host-microbe-drug interactions. Two recent studies highlight the power of this model system. In brief, these studies identified two roles for bacteria in modulating the host drug response: (1) metabolic drug activation, and (2) supplementation of vitamins or nucleotides that affect the host’s drug response. This review will summarize the main findings of both studies, as well as provide some perspective into the advantages and limitations of the C. elegans-bacteria model for the detailed characterization of host-microbiota-drug interactions.
García-González AP, Walhout AJM (2017) Worms, bugs and drugs: Caenorhabditis elegans as a model for host-microbe-drug interactions. Curr. Opin. Sys. Biol. 6, 46-50.
Marian Walhout, PhD, has received a 5-year, $4.1 million Maximizing Investigators’ Research Award (MIRA) from the National Institutes of Health to continue her study of metabolism and gene expression and how they interact.
“With this grant, we have a lot of freedom to explore different scientific avenues,” said Dr. Walhout, the Maroun Semaan Chair in Biomedical Research, professor of molecular medicine and co-director of the Program in Systems Biology.
Part of NIH’s outstanding investigator award program, MIRA provides researchers with greater stability and flexibility through extended funding, thereby enhancing scientific productivity and the chances for important breakthroughs. The specific grant awarded to the Walhout Lab is funded by the National Institute of General Medical Sciences.
The human microbiota greatly affects physiology and disease; however, the contribution of bacteria to the response to chemotherapeutic drugs remains poorly understood. Caenorhabditis elegans and its bacterial diet provide a powerful system to study host-bacteria interactions. Here, we use this system to study how bacteria affect the C. elegans response to chemotherapeutics. We find that different bacterial species can increase the response to one drug yet decrease the effect of another. We perform genetic screens in two bacterial species using three chemotherapeutic drugs: 5-fluorouracil (5-FU), 5-fluoro-2′-deoxyuridine (FUDR), and camptothecin (CPT). We find numerous bacterial nucleotide metabolism genes that affect drug efficacy in C. elegans. Surprisingly, we find that 5-FU and FUDR act through bacterial ribonucleotide metabolism to elicit their cytotoxic effects in C. elegans rather than by thymineless death or DNA damage. Our study provides a blueprint for characterizing the role of bacteria in the host response to chemotherapeutics.
García-González AP, Ritter AD, Shrestha S, Andersen EC, Yilmaz LS, Walhout AJM. (2017) Bacterial Metabolism Affects the C. elegans Response to Cancer Chemotherapeutics. Cell 169, 431-441.
The bacteria residing in your digestive tract, or your gut microbiota, may play an important role in your ability to respond to chemotherapy drugs, according to a new study by scientists at UMass Medical School. Published in Cell, the study by Marian Walhout, PhD, and colleagues shows that when a common research model, the roundworm Caenorhabditis elegans, was fed a diet of E. coli bacteria, the worms were 100 times more sensitive to the chemotherapy drug floxuridine (FUDR) than worms who were fed different bacteria. FUDR is a commonly used drug to treat colorectal cancer. READ MORE…